News

Talgat Momyshev, Director of the Eurasian Economic Commission's Technical Regulation and Accreditation Department, reported on the preliminary performance of the Eurasian Economic Union's common market of medicines and plans for 2025 at the International Eurasian Pharmaceutical Forum in Almaty.

In particular, Talgat Momyshev emphasized: "December 31 this year the transition period for submitting requests to join the common market ends. This deadline will not change. However, the conditions for transition in the States concerned are planned to be somewhat relaxed."

All EAEU medicine manufacturers have already been given the possibility to make simultaneous amendments to their marketing authorization applications during the compliance procedure, which has simplified their work.

Until the end of this year, national marketing authorizations remain valid, and amendments to national dossiers are allowed according to the rules of the EAEU States.

Talgat Momyshev noted the work of pharma inspectors of the Member States. In 2025, the first Union's GMP certificates they issued in 2021 will expire.

To ensure continuous production and supply of medicinal products to the EAEU common market, manufacturers are invited to submit requests for routine inspections in advance (at least 6–9 months prior the expiration). Then they should make sure they are included in the 2025–2026 inspection plan.

This year the Commission plans to continue its large-scale work on updating the regulation of the common market of medicines. It is planned, for example, to clarify the rules for registration and conducting trials of medicinal products, to adopt the rules of GLP-inspections, to update the Good Clinical Practice (GCP) and a number of other acts.